Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tempest Therapeutics Inc (TPST)

Tempest Therapeutics Inc (TPST)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,338
  • Shares Outstanding, K 4,927
  • Annual Sales, $ 0 K
  • Annual Income, $ -41,840 K
  • EBIT $ -36 M
  • EBITDA $ -36 M
  • 60-Month Beta -2.43
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.06

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -3.52
  • Number of Estimates 1
  • High Estimate -3.52
  • Low Estimate -3.52
  • Prior Year -4.03
  • Growth Rate Est. (year over year) +12.66%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.87 +2.09%
on 12/15/25
9.39 -68.80%
on 11/18/25
-6.45 (-68.76%)
since 11/17/25
3-Month
2.87 +2.09%
on 12/15/25
12.23 -76.04%
on 10/15/25
-6.65 (-69.42%)
since 09/17/25
52-Week
2.87 +2.09%
on 12/15/25
13.65 -78.53%
on 01/06/25
-7.34 (-71.47%)
since 12/17/24

Most Recent Stories

More News
Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

BRISBANE, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class 1 targeted and immune-mediated...

TPST : 2.93 (+0.69%)
Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

BRISBANE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class 1 targeted and immune-mediated...

TPST : 2.93 (+0.69%)
Tempest Announces Strategic Acquisition of New Dual-CAR T Programs from Factor with Simultaneous Runway Extension Projected to Mid 2027

All-stock acquisition includes clinical-stage CD19/BCMA Dual-CAR T program Acquisition will expand existing advanced clinical-stage pipeline of amezalpat (PPAR ⍺ Antagonist, Phase 3-ready) and...

TPST : 2.93 (+0.69%)
Tempest Reports Third Quarter 2025 Financial Results and Provides Business Update

BRISBANE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class 1 targeted and immune-mediated...

TPST : 2.93 (+0.69%)
Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update

Received clearance to proceed with pivotal trial of amezalpat combination therapy for first-line hepatocellular carcinoma (HCC) in China Granted orphan drug designation from the European Medicines Agency...

TPST : 2.93 (+0.69%)
Survival Data and Regulatory Greenlights Fuel Momentum in Immunotherapy Stocks

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Cancer is no longer just a disease of aging populations. Researchers are sounding the alarm over rising...

PSTV : 0.5800 (-8.96%)
ONCY : 1.0100 (-2.88%)
AIM : 1.3400 (-2.90%)
INTS : 0.4199 (-4.46%)
TPST : 2.93 (+0.69%)
ONC.TO : 1.42 (+2.16%)
Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

TPST : 2.93 (+0.69%)
After Major Oncology Conference, All Eyes Turn to Industry Innovation

/CNW/ -- After the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and...

ONCY : 1.0100 (-2.88%)
CTXR : 1.0400 (-5.45%)
TPST : 2.93 (+0.69%)
CTOR : 1.1600 (+8.41%)
CAH : 198.44 (+0.28%)
ONC.TO : 1.42 (+2.16%)
Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

TPST : 2.93 (+0.69%)
Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

TPST : 2.93 (+0.69%)

Business Summary

Tempest Therapeutics Inc. is a clinical-stage oncology company developing potentially first-in-class therapeutics which combines both targeted and immune-mediated mechanisms. Tempest Therapeutics Inc., formerly known as Millendo Therapeutics Inc., is based in Calif.

See More

Key Turning Points

3rd Resistance Point 3.09
2nd Resistance Point 3.04
1st Resistance Point 2.98
Last Price 2.93
1st Support Level 2.87
2nd Support Level 2.82
3rd Support Level 2.76

See More

52-Week High 13.65
Fibonacci 61.8% 9.53
Fibonacci 50% 8.26
Fibonacci 38.2% 6.99
Last Price 2.93
52-Week Low 2.87

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar